The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

Hypertrophic cardiomyopathy (HCM) is a common heart disease that causes the heart muscle to thicken, sometimes to the point of obstructing blood flow. HCM is not usually dangerous, but its ...

Both smoking and hypertrophic cardiomyopathy (HCM) increase your risk of negative cardiovascular outcomes. By quitting cigarettes, you can support your HCM management plan. Hypertrophic ...

Background Apical hypertrophic cardiomyopathy (HCM) is a rare variant of HCM, often considered to have a benign prognosis. This study aimed to compare the clinical characteristics and genetic ...

Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Tenaya Therapeutics, Inc. announced that it will present new data on its MYBPC3-associated hypertrophic cardiomyopathy (HCM) program at the American College of Cardiology's Annual Scientific ...

Top-line data from the second and third parts of Edgewise Therapeutics Inc.’s four-part phase II Cirrus-HCM study in hypertrophic cardiomyopathy (HCM) has produced more positive data. There was ...

“It’s exciting to see the growing real-world evidence showing how AI-enhanced ECG analysis can play a pivotal role in identifying new patients with hypertrophic cardiomyopathy,” said Milind ...

The layoffs will take place throughout 2025 and will mostly affect Tenaya’s research and manufacturing operations. The ...

KUTV — Feline Hypertrophic Cardiomyopathy (HCM) is the most common heart disease in cats, affecting felines of all breeds and ages. This condition causes the walls of the heart’s left ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top ...